NeuroCog Trials: NeuroCog Trials Introduces NCT Pathway: Next Generation eCOA For Clinical Trials

DURHAM, N.C., July 13, 2017 -- NeuroCog Trials (NCT), a clinical technology and research services company dedicated to supporting global drug development, announces the general availability of its new flagship eCOA platform, NCT Pathway. Developed with input from seasoned clinical investigators, Pathway has the dynamic technical capabilities and user-driven design to meet the needs of virtually any clinical trial, from Alzheimer's disease and schizophrenia to oncology and cardiology. The platform is currently in use by large sponsors in several late stage clinical trials.